US-based vaccine specialist, Caliber Biotherapeutics, has opened the world’s largest modular, plant-made pharmaceutical manufacturing facility at its headquarters in Bryan, Texas.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Novella and Publicis.
West Pharmaceutical Services is preparing to increase its manufacturing capacity in response to an increased demand for its Daikyo Crystal Zenith 1mL syringe system.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at A10, Crystal Pharmatech and Algos.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a new role for former Genzyme CEO and a leadership change at Astellas Europe.
Chiltern International, a global contract research organisation (CRO) has expanded its European operations with the opening of a new office in the Netherlands.
Almac Pharma Services has expanded its cold storage capacity for biopharmaceuticals, continuing the contract manufacturing organisation’s (CMO) busy expansion programme.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at PharmStar, Cephalon, Covidien and Catalent.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Catalent, Cytel and Laureate Biopharmaceutical.
Shanghai-based CRO, ChemPartner, a subsidiary of Chinese biotech outsourcing company, ShangPharma, has signed a research services agreement with China-based oncology specialists, Shenogen Pharma, to develop therapeutic antibodies for use in the treatment...
SAFC, the custom manufacturing wing of global healthcare giant Sigma Aldritch, has announced the launch of raw materials and custom services specifically developed for point-of-care (POC) diagnostics manufacture.
World Street Fundamentals (WSF), the financial research specialist, has released two industry reports highlighting the mixed fortunes of biotech firms Biodel and MannKind, but claims a “brighter decade” lies ahead for the biotech sector.
A new study suggests pressurised carbon dioxide can accelerate crystalisation during drug production, and potentially save manufacturers time and money.
US healthcare giant Johnson & Johnson (J&J) has recalled 384,000 of its insulin cartridges on concerns the products could cause serious health problems for diabetics.
Thermo Fisher Scientific has launched a predictive assay that, it claims, can assess a drug candidate’s potential to cause liver damage earlier than traditional methods.
Agilent Technolgies, the Santa Clara, US-based scientific instrument manufacturer, has acquired instrument manufacturer and contract research organisation (CRO), Biocius Life Sciences, for an undisclosed amount.
South Korea's Samsung Group has announced plans to form a 'strategic partnership' with US contract research organisation (CRO), Quintiles, as it gears up to enter the biopharma market.
Tokyo, Japan-based digital imaging specialist, Fujifilm, has agreed a deal to buy US drug giant Merck and Co's BioManufacturing Network, including two biotech manufacturing plants.
Non-clinical CRO CIT will distribute Stemina’s hES-based toxicity testing platform to pharmaceutical and cosmetics developers in Europe under an agreement announced late last week.
US Heparin maker Scientific Protein Laboratories (SPL) says it has resolved “many of the issues” addressed in the US Food and Drug Administration (FDA) warning letter it received late last month.
RecipharmCobra Biologics has received an EU patent for a genetic modification tech that allows antibiotic resistance genes to be removed after insertion is complete.
US contract research organisation (CRO) Parexel has cut its 2011 guidance, citing slower backlog conversion from projects generated by “strategic partnerships” as basis for the revision.
Oxford Biomedica has bought RecipharmCobra Biologics’ manufacturing facility in Oxford, UK, to reduce its reliance on third-party production of its gene delivery technology.
Pfizer’s Centres for Therapeutic Innovation (CTI) has teamed up with seven New York research hospitals to accelerate biomedical research into life-saving medicines, with a focus on biologics.
Genzyme will build a second manufacturing plant in Geel, Belgium to ensure it has the capacity to meet demand for its Pompe disease drugs Myozyme and Lumizyme.
French contract research organisation (CRO) CIT will work on in vitro toxicity testing for pharmaceutical and cosmetic ingredients as the newest member of the European “ScreenTox” network.
Merck plans to cash in on the biogenerics industry after forming a partnership with Parexel to develop copies of biologic drugs within its Merck BioVentures division.
Enlight Biosciences, a Boston, US-based drug discovery and development technologies company, has formed the new company, Entrega, which focuses on oral drug delivery techniques.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at BioDelivery Sciences, SOCMA and Sanofi-aventis.
Drug developers are “aggressively changing” research and development (R&D) methods in the pursuit of the next blockbuster, according to the Tufts Centre for the Study of Drug Development (Tufts CSDD).
Spectrum Pharmaceuticals and Viropro are to develop a biosimilar version of rituximab, a monoclonal antibody cancer treatment sold by Roche and Biogen Idec.
Bayer HealthCare is investing €35m ($47m) in a new centre for the biotechnological production of ‘innovative’ pharmaceuticals to be used in clinical trials.
ProJect Pharmaceutics has opened its Munich headquarters and laboratory facilities in Martinsreid, Germany, beginning business operations to transform proteins, peptides and small molecules into novel drugs.
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.